-transparent.png){kind=logo}
The absorption and transport pathways of Conjunctisan A were determined, and its mode of action clarified, by means of radioactive labeling. A dose of 0.5 ml of this drug, labeled with I131, was applied to the conjunctival sacs of rats and rabbits. After six hours there was highly significant enrichment in the ocular tissues. The highest degree of enrichment was found in the uvea, i.e., the ciliary body, choroid and retina. However, there was also moderate enrichment in the lens and the vitreous. It was proved immunologically that the radioactivity was identical with the original Conjunctisan A molecule. In particular, it as demonstrated that the enriched Conjunctisan A in the aqueous humor precipitates with the specific antibody.
J Seifert, and
R Ganser, and
A Pfleiderer, and
W Brendel
May 1975,
Medizinische Monatsschrift,
J Seifert, and
R Ganser, and
A Pfleiderer, and
W Brendel
December 1979,
Klinische Monatsblatter fur Augenheilkunde,
J Seifert, and
R Ganser, and
A Pfleiderer, and
W Brendel
June 1980,
The Japanese journal of antibiotics,
J Seifert, and
R Ganser, and
A Pfleiderer, and
W Brendel
December 1978,
The Japanese journal of antibiotics,
J Seifert, and
R Ganser, and
A Pfleiderer, and
W Brendel
September 1974,
Klinische Monatsblatter fur Augenheilkunde,
J Seifert, and
R Ganser, and
A Pfleiderer, and
W Brendel
February 1979,
Klinische Monatsblatter fur Augenheilkunde,
J Seifert, and
R Ganser, and
A Pfleiderer, and
W Brendel
March 1982,
The Japanese journal of antibiotics,
J Seifert, and
R Ganser, and
A Pfleiderer, and
W Brendel
October 1981,
Die Pharmazie,
J Seifert, and
R Ganser, and
A Pfleiderer, and
W Brendel
January 2018,
Journal of anaesthesiology, clinical pharmacology,
J Seifert, and
R Ganser, and
A Pfleiderer, and
W Brendel
November 1977,
Nippon Ganka Gakkai zasshi,
